captomize limited glp 1 GLP-1 Weight Loss Treatment GLP-1 Capsule Suppliers, Manufacturers, Factory

But the weight loss injectables landscape now includes several options: liraglutide (Saxenda, an older daily GLP-1), semaglutide (Ozempic/Wegovy, weekly), and tirzepatide (Mounjaro/Zepbound, weekly dual-agonist)

Lillys Zepbound, approved in November 2023 as the Indiana-based drug giants answer to Novo Nordisks Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its Phase 3 trial, and a mid-stage study of another Lilly experimental medicine, called retatrutide, showed 24% weight loss after just 48 weeks

PMC: PMC6015571

10.1534/genetics.119.302939 [DOI] [PMC free article] [PubMed] [Google Scholar] Izadi A., Ebrahimi S., Shirazi S., Taghizadeh S., Parizad M., Farzadi L., et al

This enhanced accessibility and ease of use can significantly boost patient engagement

Read More about Lynn M